title: Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia?
abstract: OBJECTIVE
  The aim of this study was to evaluate inflammation parameters and assess the utility of the neutrophil- lymphocyte ratio (NLR) as a simple and readily available predictor for clinical disease activity in patients with nenign prostate hyperplasia BPH. We also aimed to investigate the relationship between inflammatory parameters with α-blocker therapy response, and evaluate the potential association between NLR and the progression of benign prostatic hyperplasia (BPH).
  
  
  METHODS
  We examined 320 consecutive patients (July 2013-December 2013) admitted to our outpatient clinic with symptoms of the lower urinary tract at Bozok University. The mean age was 60 (range, 51-75) years. Complete blood count (CBC), prostate-specific antigen (PSA), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were assessed. Correlations between PSA, CRP, ESR, prostate volume, International Prostate Symptom Score (IPPS), maximum urinary flow rate (Qmax), and NLR were assessed statistically. Patients were divided into two groups: high and low risk of progression.
  
  
  RESULTS
  NLR was positively correlated with IPSS (p=0.001, r=0.265), PSA (p=0.001, r=0.194), and negatively correlated with Qmax (p<0.001, r=-0.236). High-risk patients a had a higher NLR compared with low-risk patients, based on IPSS (p<0.001), PSA (p=0.013), and Qmax (p<0.001); however, there were no significant differences between the groups in terms of age (p>0.05), and prostate volume (p>0.05).
  
  
  CONCLUSIONS
  NLR can predict BPH progression. We propose that increased inflammation is negatively associated with clinical status in BPH patients and suggest that NLR can give information along with LUTS severity which may be used as a readikly accessible marker for patient follow-up.
authors.affiliation: Department of Urology, Bozok University, School of Medicine,Yozgat, Turkey E-mail : tanikserhat@gmail.com.
authors.forename: Serhat
authors.initials: S
authors.lastname: Tanik
authors.forename: Sebahattin
authors.initials: S
authors.lastname: Albayrak
authors.forename: Kursad
authors.initials: K
authors.lastname: Zengin
authors.forename: Hasan
authors.initials: H
authors.lastname: Borekci
authors.forename: Hasan
authors.initials: H
authors.lastname: Bakirtas
authors.forename: M Abdurrahim
authors.initials: MA
authors.lastname: Imamoglu
authors.forename: Mesut
authors.initials: M
authors.lastname: Gurdal
mesh_terms: D000368:Aged; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009504:Neutrophils / Q000473:pathology*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D012372:ROC Curve
chemical_list: D017430:Prostate-Specific Antigen